한글목차

이 보고서는 세계의 감염병 진단 검사 시장에 대해 조사했으며, 시장 개요와 함께 2024-2029년까지의 예측, 지역별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 환경

• 개요
• 인구
• 연령 분포
• 거시경제 환경
• 세계 경제 전망
• 1인당 국내총생산
• 세계의 헬스케어 동향
• 감염증 사례
• 의료 제공업체
• 환자 활동

제3장 감염증 IVD 제품과 시장

제4장 세계 시장

• 개요
• 북미
• 미국
• 캐나다
• 멕시코
• 서유럽
• 독일
• 프랑스
• 영국
• 이탈리아
• 스페인
• 기타 서유럽
• 아시아태평양
• 중국
• 일본
• 인도
• 한국
• 기타 아시아태평양
• 기타 지역
• 아프리카/중동
• 중남미
• 동유럽

제5장 기업 개요

• Abbott Laboratories
• Becton Dickinson and Company
• Bio-Rad Laboratories
• bioMerieux
• BIOFIRE Diagnostics Business
• Bruker Corporation
• Danaher Corporation
• DiaSorin
• Grifols S.A.
• Hologic
• PANTHER Molecular System
• QIAGEN
• QuidelOrtho Corporation
• Solana Business
• Roche Holding
• Siemens Healthineers
• Thermo Fisher Scientific

영문목차

Stay Ahead of the Curve with "Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029": With the global demand for infectious disease IVD products projected to surge, understanding market trends is crucial for healthcare providers, investors, and industry stakeholders. This report offers a detailed analysis of the factors driving growth, including the increasing recognition of infectious diseases as a global health concern.

As infectious diseases continue to pose significant global health challenges, diagnostic testing has emerged as a vital tool in detecting and managing these threats. Today, infectious disease testing stands at the forefront of the rapidly expanding in vitro diagnostics (IVD) industry, representing one of its largest and most dynamic segments.

This comprehensive market research report from Kalorama Information delves into the world of infectious disease IVD, presenting unparalleled insights and forecasts for 2024-2029. Designed for industry professionals, investors, and market strategists, this report will equip you with the knowledge needed to stay ahead in a competitive and rapidly evolving sector.

Report Features:

• Comprehensive Market Coverage: Understand the dynamic landscape of infectious disease diagnostics, spanning key test categories such as:
  • Healthcare-Associated Infections (HAIs)
  • COVID-19
  • Hepatitis
  • STIs
  • Influenza
  • HIV/AIDS
  • Tuberculosis
  • TORCH
  • Other infectious diseases (including Dengue Fever, Emerging Infections, Fungal, Lyme Disease, Malaria, Other Parasitic, RSV, Streptococcal)
• Global Reach with Local Insights: Gain valuable perspectives on opportunities in diverse geographic regions, including North America, Western Europe, Asia/Pacific, and emerging markets across Central & South America, Africa, and the Middle East.
• Strategic Market Drivers: Explore the macroeconomic and healthcare trends driving the need for advanced diagnostics and how aging populations and globalized threats are influencing market growth.
• Competitive Intelligence: Analyze the leading players and their IVD innovations, helping you benchmark against industry leaders and identify potential partnerships or competitive advantages.

Scope and Methodology You Can Trust: Backed by Kalorama Information's extensive experience and robust analytical frameworks, this report synthesizes data from public records, epidemiological research, key competitor analysis, and economic modeling. Our insights are further enriched by expert interviews and proprietary databases, ensuring you get actionable, reliable forecasts.

Table of Contents

Chapter 1: Executive Summary

• A Mix of Traditional and Emerging Testing Technologies
• Market Drivers
• The World Infectious Disease Testing Market
  • Table 1-1: World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
  • Figure 1-1: World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
• Major Findings of the Report
  • Table 1-2: Selected Infectious Diseases, Global Incidence, Prevalence, & Mortality, 2023 (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Sexually Transmitted Diseases [Chlamydia; Gonorrhea; Herpes HSV-2; Malaria; Syphilis; Trichomoniasis]; Tuberculosis; Typhoid Fever)
  • Figure 1-2: Selected Infectious Diseases: Global Incidence of New Cases, 2023 (million) (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Sexually Transmitted Diseases; Tuberculosis; Typhoid Fever)
  • Figure 1-3: Selected Sexually Transmitted Diseases: Global Incidence of New Cases and Chronic Cases, 2023 (million) (Sexually Transmitted Diseases [Chlamydia; Gonorrhea; Herpes HSV-2; HIV/AIDS; Malaria; Syphilis; Trichomoniasis])
  • Figure 1-4: Selected Infectious Diseases: Global Deaths, 2023 (thousands) (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Tuberculosis; Typhoid Fever)
• Scope and Methodology

Chapter 2: Market Environment

• Overview
• Population
  • Table 2-1: Population by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
  • Figure 2-1: Global Population, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
• Age Distribution
  • Table 2-2: Population 50 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
  • Table 2-3: Population 65 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
• Macroeconomic Environment
• Global Economic Outlook
  • Table 2-4: Gross Domestic Product by Country, 2023-2029 ($ billion) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
• Per Capita Gross Domestic Product
  • Table 2-5: Per Capita Gross Domestic Product by Country, 2023-2029 (dollars) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
• Global Healthcare Trends
• Infectious Disease Cases
  • Table 2-6: Number of Infectious Disease Cases by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
  • Figure 2-2: Number of Global Infectious Disease Cases, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
• Medical Providers
  • Table 2-7: Medical Providers, Selected Countries, 2021 (Africa/M.E.; Canada; Central/South America; China; Eastern Europe; France; Germany; India; Italy; Japan; Mexico; Other Asia/Pacific; Other Western Europe; South Korea; Spain; United States)
• Patient Activity
  • Hospital Admissions
  • Table 2-8: Hospital Admissions by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
  • Inpatient Days
  • Table 2-9: Inpatient Days by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
  • Outpatient Consultations
  • Table 2-10: Outpatient Consultations by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
  • IVD Tests
  • Table 2-11: IVD Tests by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
  • Figure 2-3: In Vitro Diagnostic (IVD) Tests, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)

Chapter 3: Infectious Disease IVD Products & Markets

• Overview
  • Table 3-1: Global Infectious Disease IVD Products Demand by Type, 2024-2029 ($ million) (COVID-19; Healthcare-Associated Infections [HAIs]; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Figure 3-1: Global Infectious Disease IVD Products Demand by Disease/Area, 2024-2029 ($ million) (COVID-19; Healthcare-Associated Infections [HAIs]; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Healthcare-Associated Infections (HAIs)
  • Table 3-2: Global Healthcare-Associated Infection (HAIs) IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: C. diff, MRSA, Sepsis, VRE, Other HAIs; Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
• Clostridium difficile (C. diff)
• Sepsis
• Methicillin-Resistant Staphylococcus Aureus (MRSA)
• Vancomycin-Resistant Enterococcus (VRE)
• Other HAIs
• COVID-19
  • Table 3-3: Global COVID-19 IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular Tests)
• Hepatitis IVD Products
  • Table 3-4: Global Hepatitis IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: Hepatitis B, Hepatitis C, Other; Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular)
• Sexually Transmitted Infections (STIs)
  • Table 3-5: Global Sexually Transmitted Infection (STI) IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: Chlamydia, Gonorrhea, HPV, HSV-2 [Herpes Simplex], Syphilis, Other STIs; Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
• Human Papillomavirus (HPV)
• Chlamydia Trachomatis (Chlamydia)
• Gonorrhea
• Herpes Simplex Virus 2 (HSV-2)
• Syphilis
• Other Sexually Transmitted Disease (STD) IVD Products
• Influenza
  • Table 3-6: Global Influenza IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
• HIV/AIDS IVD Products
  • Table 3-7: Global HIV/AIDS IVD Products Demand, 2024-2029 ($ million) (Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular)
• Tuberculosis (TB)
  • Table 3-8: Global Tuberculosis IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
• TORCH
  • Table 3-9: Global TORCH IVD Products Demand, 2024-2029 ($ million)
• All Other Infectious Disease IVD Products
  • Table 3-10: Global Other Infectious Disease IVD Products Demand, 2024-2029 ($ million) (Dengue Fever; Emerging Infections; Fungal; Lyme Disease; Malaria; Other Parasitic; RSV; Streptococcal; All Other)
• Malaria
• Emerging Infections
• Chikungunya
• Fungal Infections
• Other Parasitic Conditions
• Lyme Disease
• Respiratory Syncytial Virus (RSV)
• Streptococcal Infections
• Dengue Fever
• All Other Products
• Global Infectious Disease IVD Technologies
  • Table 3-11: Global Infectious Disease IVD Products Demand by Technology, 2024-2029 ($ million) (Immunoassay, Microbiology, Molecular)
• Immunoassays
  • Table 3-12: Global Immunoassay Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other)
• Molecular Technologies
  • Table 3-13: Global Molecular Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; Tuberculosis; Other)
• Microbiological Testing
  • Table 3-14: Global Microbiology Infectious Disease IVD Products Demand, 2024-2029 ($ million) (HAIs/Sepsis; Influenza; STIs; Tuberculosis; Other)
• Pathogen ID/AST Techniques
  • Table 3-15: Global Microbiology ID/AST IVD Products Demand, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Auto; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
• Automated ID/AST Products
• Manual Panels & Reagents
• Producers
• Global Infectious Disease IVD Demand by Market
  • Table 3-16: Global Infectious Disease IVD Products Demand by Site, 2024-2029 ($ million) (Blood Screens; Laboratory; Point-of-Care)
  • Table 3-17: Global Laboratory Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Table 3-18: Global Point-of-Care Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; Tuberculosis; Other Infections)

Chapter 4: Global Markets

• Overview
  • Table 4-1: Infectious Disease IVD Products Demand, by Country, 2024-2029 ($ million) (Asia/Pacific [China, India, Japan, South Korea, Other APAC]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other Western Europe]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
• North America
  • Table 4-2: North America: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• United States
  • Table 4-3: United States: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Canada
  • Table 4-4: Canada: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Mexico
  • Table 4-5: Mexico: Infectious Disease IVD Products Demand by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Western Europe
  • Table 4-6: Western Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Germany
  • Table 4-7: Germany: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• France
  • Table 4-8: France: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• United Kingdom
  • Table 4-9: United Kingdom: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Italy
  • Table 4-10: Italy: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Spain
  • Table 4-11: Spain: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Other Western Europe
  • Table 4-12: Other Western Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Switzerland
  • Netherlands
  • Sweden
  • Belgium
  • Austria
  • Denmark
  • Norway
  • Portugal
  • Ireland
  • Greece
  • Finland
  • All Other Countries & Territories
• Asia/Pacific
  • Table 4-13: Asia/Pacific: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• China
  • Table 4-14: China: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Japan
  • Table 4-15: Japan: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• India
  • Table 4-16: India: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• South Korea
  • Table 4-17: South Korea: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Other Asia/Pacific
  • Table 4-18: Other Asia/Pacific: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Malaysia
  • Pakistan
  • Vietnam
  • All Other Countries & Territories
• Other Regions
  • Table 4-19: Other Regions: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
• Africa/Middle East
  • Table 4-20: Africa/Middle East: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Turkey
  • Saudi Arabia
  • Iran
  • Egypt
  • Iraq
  • Nigeria
  • South Africa
  • Israel
  • United Arab Emirates
  • All Other Countries & Territories
• Central & South America
  • Table 4-21: Central & South America: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Brazil
  • Argentina
  • Colombia
  • Peru
  • Chile
  • All Other Countries & Territories
• Eastern Europe
  • Table 4-22: Eastern Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Russia
  • Poland
  • Romania
  • Czech Republic
  • Hungary
  • All Other Eastern Europe Countries

Chapter 5: Company Profiles

• Abbott Laboratories
• Infectious Diseases - Molecular
• COVID-19
• HIV Point of Care
• Blood Bank
• Becton Dickinson and Company
• Molecular Microbiology
• Traditional Microbiology - ID/AST
• Blood Culture
• Hospital Acquired Infections
• Molecular Microbiology
• Traditional Microbiology - ID/AST
• Blood Culture
• Mass Spectrometry
• Bio-Rad Laboratories
• Immunoassays
• bioMerieux
• Traditional Microbiology
• Blood Culture
• Immunoassays
• BIOFIRE Diagnostics Business
• Mass Spectrometry
• Bruker Corporation
• Danaher Corporation
• Tuberculosis
• Microbiology
• POC Testing Developments
• DiaSorin
• Recent Deals and Announcements
• Grifols S.A.
• Blood Transfusion Business
• Hologic
• PANTHER Molecular System
• HIV Testing
• Sexually Transmitted Infections
• Infectious Diseases
• QIAGEN
• Tuberculosis
• Molecular Expansion
• QuidelOrtho Corporation
• Solana Business
• Molecular - Savanna
• COVID-19
• Roche Holding
• Immunoassays
• COVID-19
• Blood Screening
• HPV
• Other Recent Developments
• Siemens Healthineers
• Thermo Fisher Scientific
• Microbiology
• Molecular Test Business
• COVID-19